Hyperthermic intraperitoneal chemotherapy in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei: a 10-year treatment experience in China

Table 2 Univariate analysis affecting overall survival after CRS

Variables	Log-rank P value of univariate analysis
	Overall	LG-MCP	HG-MCP	HGMC-S
	P value	P value	P value	P value
Gender (male vs. female)	0.000*	0.000*	0.002*	0.804
Age (< 59 vs. ≥59, years)	0.480	0.842	0.434	0.305
Operation time (< 490 vs. ≥490, min)	0.061	0.333	0.153	0.965
Blood loss (< 1500 vs. ≥1500, ml)	0.329	0.056	0.424	0.991
PCI (< 31 vs. ≥31)	0.385	0.729	0.144	0.035*
CCR (2 vs. 3)	0.005*	0.010*	0.096	0.111
HIPEC (yes vs. no)	0.032*	0.019*	0.533	0.262
HIPEC drug regimen (MMC vs. DDP vs. MMC + DDP)	0.205	0.065	0.847	0.381
PSC (yes vs. no)	0.512	0.893	0.412	0.483
Previous surgery (yes vs. no)	0.493	0.794	0.529	0.312
Pathological grade (LG-MCP vs. HG-MCP vs. HGMC-S)	0.000*

CRS cytoreductive surgery, PCI peritoneal cancer index, CCR completeness of cytoreduction, HIPEC hyperthermic intraperitoneal chemotherapy, MMC mitomycin, DDP cisplantin, PSC previous systemic chemotherapy, LG-MCP low-grade mucinous carcinoma peritonei, HG-MCP high-grade mucinous carcinoma peritonei, HGMC-S high-grade mucinous carcinoma peritonei with signet ring cells
*P < 0.05

ISSN: 1750-1172